Neumora Therapeutics (NMRA) EPS (Weighted Average and Diluted) (2022 - 2026)
Neumora Therapeutics' quarterly EPS (Weighted Average and Diluted) came in at -$0.3 in Q1 2026, up 28.57% year-on-year from -$0.23 in Q1 2025, and up 14.29% quarter-over-quarter from -$0.35 in Q4 2025.
Neumora Therapeutics has reported EPS (Weighted Average and Diluted) for 5 years, with the latest figure at -$0.3 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 28.57% year-over-year to -$0.3; the trailing twelve-month figure through Mar 2026 stood at -$1.33 (up 17.39% YoY), and the FY2025 full-year result was -$1.45, up 5.23% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.3, up from -$0.35 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.04 in Q4 2023, with the low at -$1.28 in Q2 2023.
- Average EPS (Weighted Average and Diluted) over 5 years is -$0.6, with a median of -$0.37 recorded in 2024.
- Year-over-year, EPS (Weighted Average and Diluted) surged 95.92% in 2023 and slumped 825.0% in 2024.
- Tracing NMRA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.98 in 2022, then surged by 95.92% to -$0.04 in 2023, then tumbled by 825.0% to -$0.37 in 2024, then gained by 5.41% to -$0.35 in 2025, then increased by 14.29% to -$0.3 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.3 (Q1 2026), -$0.35 (Q4 2025), and -$0.35 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - | -0.30 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.30 |
| Dec 31, 2025 | -0.35 |
| Sep 30, 2025 | -0.35 |
| Jun 30, 2025 | -0.33 |
| Mar 31, 2025 | -0.42 |
| Dec 31, 2024 | -0.37 |
| Sep 30, 2024 | -0.45 |
| Jun 30, 2024 | -0.37 |
| Mar 31, 2024 | -0.34 |
| Dec 31, 2023 | -0.04 |
| Sep 30, 2023 | -1.14 |
| Jun 30, 2023 | -1.28 |
| Mar 31, 2023 | -1.22 |
| Dec 31, 2022 | -0.98 |
| Sep 30, 2022 | -1.06 |